Traditional drug development and discovery has not kept pace with threats from emerging
and re-emerging diseases such as Ebola virus, MERS-CoV and more recently, SARS-CoV …

Compared with traditional de novo drug discovery, drug repurposing has become an
attractive drug discovery strategy due to its low-cost and high efficiency. Through a …

Application of materials capable of energy harvesting to increase the efficiency and
environmental adaptability is sometimes reflected in the ability of discovery of some traces in …

The SARS-CoV-2 coronavirus outbreak continues to spread at a rapid rate worldwide. The
main protease (Mpro) is an attractive target for anti-COVID-19 agents. Unexpected …

Antivirals targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could
improve treatment of COVID-19. We evaluated the efficacy of clinically relevant hepatitis C …

Some recent studies showed that severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) infections and idiopathic pulmonary fibrosis (IPF) disease might stimulate each other …

Saquinavir was the first protease inhibitor developed for HIV therapy, and it changed the
standard of treatment for this disease to a combination of drugs that ultimately led to …

Abstract Papain-Like Protease (PLpro) is a key protein for SARS-CoV-2 viral replication
which is the cause of the emerging COVID-19 pandemic. Targeting PLpro can suppress viral …

In recent years, small molecule inhibition of LDHA (Lactate Dehydrogenase A) has evolved
as an appealing option for anticancer therapy. LDHA catalyzes the interconversion of …

The coronavirus infectious disease-2019 (COVID-19) has overwhelmed like a shock wave in
a completely unprepared world. Despite coronavirus infections were involved in previous …